Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study

被引：0

作者：

Fleischmann, Roy ^{[1
]}

Burmester, Gerd-Rudiger ^{[2
]}

Combe, Bernard ^{[3
]}

Curtis, Jeffrey R. ^{[4
]}

Hal, Stephen ^{[5
]}

Haraoui, Boulos ^{[6
]}

van Vollenhoven, Ronald ^{[7
]}

Cioffi, Christopher ^{[8
]}

Ecoffet, Cecile ^{[9
]}

Ionescu, Lucian ^{[9
]}

Gervitz, Leon ^{[10
]}

Peterson, Luke ^{[8
]}

Smolen, Josef ^{[11
,12
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA

[2] Charite Univ Med Berlin, Berlin, Germany

[3] Montpellier Univ Hosp, Montpellier, France

[4] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA

[5] Monash Univ, Cabrini Med Ctr, Melbourne, Vic, Australia

[6] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada

[7] Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands

[8] UCB Pharma, Raleigh, NC USA

[9] UCB Pharma, Brussels, Belgium

[10] UCB Pharma, RA Patient Value Mission, Brussels, Belgium

[11] Med Univ Vienna, Vienna, Austria

[12] Hietzing Hosp, Vienna, Austria

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2987

引用

页数：3

共 50 条

[1] Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Fleischmann, Roy
Burmester, Gerd-Ruediger
Combe, Bernard
Curtis, Jeffrey R.
Hall, Stephen
Haraoui, Boulos
van Vollenhoven, Ronald
Cioffi, Christopher
Ecoffet, Cecile
Ionescu, Lucian
Gervitz, Leon
Peterson, Luke
Smolen, Josef
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[2] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Smolen, Josef S.
Burmester, Gerd-Ruediger
Combe, Bernard
Curtis, Jeffrey R.
Hall, Stephen
Haraoui, Boulos
van Vollenhoven, Ronald
Cioffi, Christopher
Ecoffet, Cecile
Gervitz, Leon
Ionescu, Lucian
Peterson, Luke
Fleischmann, Roy
[J]. LANCET, 2016, 388 (10061): : 2763 - 2774
[3] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
Smolen, J. S.
Burmester, G-R
Combe, B.
[J]. LANCET, 2016, 388 (10061): : 2742 - 2742
[4] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
Smolen, J. S.
Burmester, G-R
Combeet, B.
[J]. LANCET, 2017, 389 (10068): : E2 - E2
[5] A recent Head-to-Head Study evaluates Efficacy and Safety of Ustekinumab versus Adalimumab
不详
[J]. VISCERAL MEDICINE, 2018, 34 (04) : 319 - 319
[6] HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB ON BACKGROUND METHOTREXATE IN RA: TWO YEAR RESULTS FROM THE AMPLE STUDY
Schiff, M.
Weinblatt, M.
Valente, R.
van der Heijde, D.
Citera, G.
Elegbe, A.
Maldonado, M.
Fleischmann, R.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 64 - 64
[7] Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Schiff, Michael
Weinblatt, Michael E.
Valente, Robert
van der Heijde, Desiree
Citera, Gustavo
Elegbe, Ayanbola
Maldonado, Michael
Fleischmann, Roy
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 86 - 94
[8] HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VS ADALIMUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: KEY EFFICACY AND SAFETY RESULTS FROM THE AMPLE TRIAL
Weinblatt, Michael E.
Schiff, Michael H.
Fleischmann, Roy
Valente, Robert
van der Heijde, Desiree
Citera, Gustavo
Zhao, Cathy
Maldonado, Michael A.
[J]. RHEUMATOLOGY, 2013, 52 : 45 - 46
[9] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
Mease, Philip
Smolen, Josef
Kavanaugh, Arthur
Nash, Peter
Gallo, Gaia
Liu-Leage, Soyi
Sapin, Christophe
Genovese, Mark
[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
[10] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease, P. J.
Smolen, J. S.
Kavanaugh, A.
Nash, P.
Gallo, G.
Leage, S. Liu
Sapin, C.
Genovese, M. C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698

← 1 2 3 4 5 →